JP MORGAN/PUT/VERTEX PHARMACEUTICALS/265/0.1/17.01.25 | Market Closed - Börse Stuttgart 12:18:51 07/06/2024 pm IST | ||
| 0.086 EUR | -1.15% |
|
| Current month | -54.74% | ||
| 1 month | -69.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 0.086 | -1.15% |
| 06/24/06 | 0.087 | -10.31% |
| 05/24/05 | 0.097 | -19.17% |
| 04/24/04 | 0.12 | -20.00% |
| 03/24/03 | 0.15 | -21.05% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 12:18 pm IST
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL07U2 |
| ISIN | DE000JL07U21 |
| Date issued | 12/04/2023 |
| Strike | 265 $ |
| Maturity | 17/01/2025 (223 Days) |
| Parity | 10 : 1 |
| Emission price | 2.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.79 € |
|---|---|
| Lowest since issue | 0.086 € |
| Spread | 0.703 € |
| Spread % | 87.88% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Warrants
- Warrant
